[Biomarkers of renal impairment and their application in renal function monitoring during treatment with nucleos(t)ide analogues].
Currently, nucleos(t)ide analogues (NAs) are the major drugs for the antiviral treatment of chronic hepatitis B (CHB), including lamivudine, adefovir dipivoxil, telbivudine, entecavir, and tenofovir disoproxil. Since many patients need to take NAs orally for a long time to inhibit viral replication, the safety of long-term administration is an important factor for selecting drugs in clinical practice. In recent years, some studies have been focusing on the impact of long-term administration of NAs on glomerular filtration function and renal tubular function in such patients. At the same time, more and more biomarkers for evaluating renal impairment have been used in clinical practice, but the applicability of most biomarkers in CHB patients remains uncertain. This review describes the biomarkers that are currently used or have a potential clinical value and investigates the application of such biomarkers in CHB patients in future.
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
H S
HS
Li
H
H
Ma
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D005919:Glomerular Filtration Rate / Q000187:drug effects* / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D009705:Nucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D009711:Nucleotides / Q000009:adverse effects / Q000627:therapeutic use*
D000998:Antiviral Agents; D015415:Biomarkers; D009705:Nucleosides; D009711:Nucleotides